PMID: 9423924Jan 10, 1998Paper

The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome

Neuropharmacology
W P WatsonH J Little

Abstract

The effects of the anticonvulsant, gabapentin, were investigated, in mice, on the withdrawal convulsive behaviour and anxiety-related behaviour that are produced by cessation of prolonged intake of ethanol. When given at 50 or 100 mg/kg, this compound decreased the rise in handling-induced hyperexcitability which occurs during the withdrawal period; the effects were most pronounced for the first 4 hr after administration. Gabapentin also decreased the convulsive response to an audiogenic stimulus during the withdrawal period. The elevated plus-maze, with both traditional and ethological indices of activity was used as a test of anxiety-related behaviour after cessation of chronic ethanol treatment. Gabapentin, at 50 and 100 mg/kg, was found to decrease some, although not all, of the signs of withdrawal-induced anxiety. At doses up to and including 200 mg/kg, gabapentin had no effect on motor co-ordination or spontaneous locomotor activity in control animals. The results demonstrated that gabapentin has a selective action in decreasing both convulsive and anxiety-related aspects of withdrawal behaviour after chronic ethanol treatment. It is possible that further studies with this compound may shed further light on the mechanisms...Continue Reading

References

Jan 1, 1979·Brain & Development·S MiyakeY Ike
Jan 1, 1990·Psychopharmacology·A R GreenA J Cross
Apr 21, 1994·Drug and Therapeutics Bulletin
Jan 8, 1994·Lancet·D Chadwick
Mar 14, 1994·Neuroscience Letters·J D Kocsis, O Honmou
Nov 15, 1993·European Journal of Pharmacology·R J ThurlowG N Woodruff
Feb 15, 1993·European Journal of Pharmacology·N Suman-ChauhanG N Woodruff
Feb 15, 1993·European Journal of Pharmacology·D R HillG N Woodruff

❮ Previous
Next ❯

Citations

Jan 26, 2002·Journal of Neurobiology·Sandra M Leal, Wendi S Neckameyer
Sep 10, 2004·Current Psychiatry Reports·Hugh Myrick, Raymond Anton
Aug 15, 2000·Neuroscience and Biobehavioral Reviews·K C Ross, J R Coleman
Sep 18, 2002·Brain Research. Developmental Brain Research·Craig J Slawecki, Cindy L Ehlers
Feb 21, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vasilis BozikasAthanasios Karavatos
Oct 28, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Giovanni AddoloratoAntonello Bonci
Feb 13, 2010·Addiction Biology·Markus HeiligHoward C Becker
Dec 24, 2005·Epilepsy Currents·Michael A Rogawski
May 30, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Marisa RobertoGeorge F Koob
Sep 3, 2011·Psychopharmacology·Serena StopponiRoberto Ciccocioppo
Oct 2, 2003·Journal of Clinical Psychopharmacology·Udo BonnetMarkus Gastpar
Nov 22, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lorenzo LeggioRobert M Swift
Feb 17, 2005·Alcoholism, Clinical and Experimental Research·Bankole A JohnsonHugh Myrick
Jul 15, 2004·Alcoholism, Clinical and Experimental Research·C L KliethermesJ C Crabbe
Jun 3, 2009·Alcoholism, Clinical and Experimental Research·Hugh MyrickCarrie L Randall
Jan 26, 2007·Alcoholism, Clinical and Experimental Research·Hugh MyrickScott Henderson
Nov 19, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michael Soyka, Jochen Mutschler
Feb 28, 2006·Alcoholism, Clinical and Experimental Research·Bankole A JohnsonNassima Ait-Daoud
Nov 2, 2006·Basic & Clinical Pharmacology & Toxicology·Bogusława Pietrzak, Elzbieta Czarnecka
Sep 14, 2016·Genes, Brain, and Behavior·K M Holleran, D G Winder
Dec 23, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael SoykaUNKNOWN WFSBP Task Force on Treatment Guidelines for Substance Use Disorders
May 15, 2015·The Annals of Pharmacotherapy·Jonathan G LeungKathryn M Schak
Aug 3, 2000·Muscle & Nerve·N BonevaZ Argov
Mar 8, 2017·Psychopharmacology·Samantha R Spierling, Eric P Zorrilla
Oct 22, 2020·Mayo Clinic Proceedings. Innovations, Quality & Outcomes·Ruth E BatesSimon Kung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Progress in Neuro-psychopharmacology & Biological Psychiatry
Vasilis BozikasAthanasios Karavatos
Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse
John VorisQueen J Flowers
© 2021 Meta ULC. All rights reserved